SCHEMBL12940481

SCHEMBL12940481

Cn1ncc(Br)c1C1CC1

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MGLL Q99685 3/20 0.31
KAT2B Q92831 1/20 0.31
HTT P42858 1/20 0.30
KEAP1 Q14145 1/20 0.30
NFE2L2 Q16236 1/20 0.30
MAP4K1 Q92918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3685143 0.90 KAT2B (0.34) LMNAPOLBKAT2B
SCHEMBL12967352 0.77 MAP4K4 (0.40) MGLLHTTKEAP1NFE2L2MAP4K1
SCHEMBL21863532 0.75 MGLL (0.31) MGLLKEAP1NFE2L2MAP4K1
SCHEMBL12539504 0.74 PROKR1 (0.39) LMNAPOLB
SCHEMBL26034466 0.72 PLAT (0.35) MGLLKEAP1NFE2L2
SCHEMBL12939806 0.72 MGLL (0.30) MGLL
SCHEMBL21848989 0.72 MGLL (0.30) MGLL
SCHEMBL28920931 0.71 ALDH1A1 (0.35) LMNAPOLBSMN1; SMN2MGLLKEAP1
SCHEMBL31192972 0.71 KDM4E (0.30)
SCHEMBL17624319 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655284-A1 MICROBIOCIDAL PYRAZOLE DERIVATIVES Syngenta Crop Protection AG (CH) 2025-12-03 EP disclosed
EP-4643949-A2 NICOTINAMIDE RIPK1 INHIBITORS AbbVie Inc. (US) 2025-11-05 EP disclosed
US-20240360099-A1 NICOTINAMIDE RIPK1 INHIBITORS ABBVIE INC. 2024-10-31 US disclosed
WO-2024156886-A1 MICROBIOCIDAL PYRAZOLE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2024-08-02 WO disclosed
CN-117460722-A Nicotinamide RIPK1 inhibitors 艾伯维公司 2024-01-26 CN disclosed
EP-4301744-A1 NICOTINAMIDE RIPK1 INHIBITORS AbbVie Inc. (US) 2024-01-10 EP disclosed
CN-117279896-A Amino substituted pyrido ring compounds, preparation method and application thereof 劲方医药科技(上海)有限公司 2023-12-22 CN disclosed
US-11767310-B2 Nicotinamide RIPK1 inhibitors ABBVIE INC. (US) 2023-09-26 US disclosed
US-11767310-B2 Nicotinamide RIPK1 inhibitors ABBVIE INC. (US) 2023-09-26 US disclosed
WO-2023143482-A1 2-AMINOPYRIMIDINE COMPOUND OR SALT, PREPARATION METHOD THEREFOR AND USE THEREOF 上海辉启生物医药科技有限公司 2023-08-03 WO disclosed
US-20230127127-A1 NICOTINAMIDE RIPK1 INHIBITORS ABBVIE INC. 2023-04-27 US disclosed
US-20230127127-A1 NICOTINAMIDE RIPK1 INHIBITORS ABBVIE INC. 2023-04-27 US disclosed
WO-2023018643-A1 NICOTINAMIDE RIPK1 INHIBITORS ABBVIE INC. (US) 2023-02-16 WO disclosed
WO-2023018643-A1 NICOTINAMIDE RIPK1 INHIBITORS ABBVIE INC. (US) 2023-02-16 WO disclosed
WO-2022214044-A1 AMINE-SUBSTITUTED PYRIDINE FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF 劲方医药科技(上海)有限公司 2022-10-13 WO disclosed
EP-2445909-B1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INT (DE) 2013-11-13 EP disclosed
US-20120252817-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-04 US disclosed
US-20120252817-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360099-A1 NICOTINAMIDE RIPK1 INHIBITORS RIPK1, RIPK2, RIPK4 LMNA 1936/4885POLB 2859/4885SMN1; SMN2 3077/4885
US-20120252817-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES ARG1, COL14A1, HPGDS LMNA 3234/4885POLB 4566/4885SMN1; SMN2 3967/4885
US-20230127127-A1 NICOTINAMIDE RIPK1 INHIBITORS RIPK1, RIPK2, RIPK4 LMNA 1936/4885POLB 2859/4885SMN1; SMN2 3077/4885
US-11767310-B2 Nicotinamide RIPK1 inhibitors RIPK1, RIPK2, RIPK4 LMNA 1936/4885POLB 2859/4885SMN1; SMN2 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.